title: Teicoplanin in the treatment of infection caused by gram-positive organisms.
abstract: Teicoplanin was used to treat 94 hospital in-patients of confirmed or presumed Gram-positive infections over a period of 12 months. Eighty-five patients were subsequently found to be evaluable; 31 had soft tissue infections, 10 endocarditis, 8 urinary tract infections, 12 septicaemias, 2 chest infections, 7 osteomyelitis or septic arthritis, and 15 were immunosuppressed patients with infected Hickman line site infections. The cure rate of the 85 evaluable episodes was 90% (76 cured). Teicoplanin was well tolerated intravenously and intramuscularly. Adverse reactions occurred in five patients. One patient suffered high tone hearing loss, two patients suffered transient rash, one developed a drug fever and one patient who had concomitant gentamicin developed vestibular damage. It is concluded that teicoplanin is a relatively safe and effacacious treatment for Gram-positive infection.
authors.forename: A H
authors.initials: AH
authors.lastname: Williams
authors.forename: R N
authors.initials: RN
authors.lastname: Grüneberg
authors.forename: A
authors.initials: A
authors.lastname: Webster
authors.forename: G L
authors.initials: GL
authors.lastname: Ridgway
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D006020:Glycopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006094:Gram-Positive Bacteria; D006801:Humans; D017334:Teicoplanin
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin